Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Bikalm

Base Information Edit
  • Chemical Name:Bikalm
  • CAS No.:99294-93-6
  • Molecular Formula:2(C19H21N3O).C4H6O6
  • Molecular Weight:764.86
  • Hs Code.:2933996500
  • European Community (EC) Number:629-694-9
  • DSSTox Substance ID:DTXSID00912795
  • NCI Thesaurus Code:C29553
  • RXCUI:221183
  • Mol file:99294-93-6.mol
Bikalm

Synonyms:Ambien;Amsic;Bikalm;Dalparan;Imidazo(1,2-a)pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-;N,N,6-trimethyl-2-(4-methylphenyl)imidazo(1,2a)pyridine-3-acetamide hemitartrate;SL 80.0750;SL 800750 23 N;SL-800750-23-N;Stilnoct;Stilnox;zodormdura;Zoldem;Zolirin;Zolpi Lich;Zolpi-Lich;zolpidem;Zolpidem 1A Pharma;Zolpidem AbZ;Zolpidem Hemitartrate;zolpidem tartrate;Zolpimist;Zolpinox

 This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

Chemical Property of Bikalm Edit
Chemical Property:
  • Appearance/Colour:White to off-white crystalline powder 
  • Melting Point:196oC /Zolpidem/ 
  • PSA:152.67000 
  • LogP:1.12620 
  • Storage Temp.:2-8°C 
  • Solubility.:Slightly soluble in water, sparingly soluble in methanol, practically insoluble in methylene chloride. 
  • Hydrogen Bond Donor Count:4
  • Hydrogen Bond Acceptor Count:8
  • Rotatable Bond Count:6
  • Exact Mass:457.18490021
  • Heavy Atom Count:33
  • Complexity:551
Purity/Quality:
Safty Information:
  • Pictogram(s): IrritantXi 
  • Hazard Codes:Xi,T,F 
  • Statements: 36/37/38-39/23/24/25-23/24/25-11 
  • Safety Statements: 26-36-45-36/37-16-7 
MSDS Files:

SDS file from LookChem

Useful:
  • Canonical SMILES:CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C.C(C(C(=O)O)O)(C(=O)O)O
  • Isomeric SMILES:CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
  • Recent ClinicalTrials:The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion
  • Recent EU Clinical Trials:A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects with Insomnia Disorder
  • Recent NIPH Clinical Trials:A prospective study examining patient satisfaction and sleep analysis data in drug therapy for patients with insomnia.
  • Clinical Use Insomnia (short-term treatment)
  • Drug interactions Potentially hazardous interactions with other drugs Antibacterials: metabolism accelerated by rifampicin. Antidepressants: increased sedative effects with sertraline. Antipsychotics: enhanced sedative effects. Antivirals: concentration increased by ritonavir (risk of extreme sedation and respiratory depression) - avoid concomitant use.